Back to search

Article

Blinatumomab as maintenance therapy for pediatric acute B-lymphoblastic leukemia in the setting of asparaginase-associated pancreatitis

2024-05-27

Abstract excerpt

Modern chemotherapy for pediatric acute B-lymphoblastic leukemia (B-ALL), including a maintenance phase on the backbone of oral antimetabolite administration, has resulted in a generally excellent prognosis for newly diagnosed disease. However, therapy-related toxicities may preclude a patient’s ability to safely receive traditional chemotherapy. We report the case of a child with B-ALL unable to tolerate oral ant...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
0cf4b5c4-48d5-54ea-9f1e-3eabc17064f7
DOI
10.22541/au.171685038.87563985/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Blinatumomab as maintenance therapy for pediatric acute B-lymphoblastic leukemia in the setting of asparaginase-associated pancreatitisDOI 10.22541/au.171685038.87563985/v1
Multi-courses of Blinatumomab combined with reduced dose chemotherapy has been successfully used in chemo intolerant middle to high-risk pediatric B-ALL patients with invasive fungal diseaseSemantic proximity
Hyper-CVAD and Sequential Blinatumomab in Adults with Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia: Results from a Phase II StudySemantic proximity
Leukemia burden impacts the efficacy and toxicity of blinatumomab in pediatric B-cell acute lymphoblastic leukemiaSemantic proximity
Venetoclax in combination with a pediatric-inspired regimen for the treatment of newly diagnosed adults with Philadelphia chromosome-negative acute lymphoblastic leukemiaSemantic proximity
Leukemia burden impacts the efficacy and toxicity of blinatumomab in pediatric B-cell acute lymphoblastic leukemiaSemantic proximity
Pretransplant Blinatumomab Improves Outcomes in B Cell Acute Lymphoblastic Leukemia Patients Who Undergo Allogeneic Hematopoietic Cell TransplantationSemantic proximity
The characteristics and risk factors of asparaginase-associated pancreatitis in pediatric acute lymphoblastic leukemiaSemantic proximity
Tumor-intrinsic and -extrinsic determinants of response to blinatumomab in adults with B-ALL.Semantic proximity
Lineage switch under blinatumomab treatment of relapsed common acute lymphoblastic leukemia without MLL rearrangementSemantic proximity
The orally bioavailable GSPT1/2 degrader SJ6986 exhibits in vivo efficacy in acute lymphoblastic leukemiaSemantic proximity
The combination of a tyrosine kinase inhibitor and blinatumomab in patients with Philadelphia chromosome–positive acute lymphoblastic leukemia or Philadelphia chromosome‐like acute lymphoblastic leukemiaSemantic proximity
Rituximab in B-Lineage Adult Acute Lymphoblastic LeukemiaSemantic proximity
Select a neighboring publication to make it the new centre.